NASDAQ:RMTI Rockwell Medical (RMTI) Stock Price, News & Analysis → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Free RMTI Stock Alerts $1.66 +0.02 (+1.21%) (As of 12:31 PM ET) Add Compare Share Share Today's Range$1.60▼$1.6650-Day Range$1.23▼$1.7152-Week Range$1.16▼$6.24Volume197,293 shsAverage Volume229,015 shsMarket Capitalization$48.68 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Rockwell Medical alerts: Email Address Rockwell Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside329.4% Upside$7.00 Price TargetShort InterestHealthy2.15% of Float Sold ShortDividend StrengthN/ASustainability-2.35Upright™ Environmental ScoreNews Sentiment0.10Based on 23 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.11) to $0.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.25 out of 5 starsMedical Sector159th out of 939 stocksPharmaceutical Preparations Industry62nd out of 433 stocks 3.5 Analyst's Opinion Consensus RatingRockwell Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Rockwell Medical has a forecasted upside of 329.4% from its current price of $1.63.Amount of Analyst CoverageRockwell Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.15% of the float of Rockwell Medical has been sold short.Short Interest Ratio / Days to CoverRockwell Medical has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rockwell Medical has recently decreased by 9.42%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRockwell Medical does not currently pay a dividend.Dividend GrowthRockwell Medical does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRockwell Medical has received a 58.29% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Iron deficiency medication" and "Clinical research services for deficiency diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rockwell Medical is -2.35. Previous Next 2.3 News and Social Media Coverage News SentimentRockwell Medical has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Rockwell Medical this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for RMTI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Rockwell Medical to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rockwell Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Rockwell Medical is held by insiders.Percentage Held by InstitutionsOnly 23.31% of the stock of Rockwell Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rockwell Medical are expected to grow in the coming year, from ($0.11) to $0.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rockwell Medical is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rockwell Medical is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRockwell Medical has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Rockwell Medical Stock (NASDAQ:RMTI)Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.Read More RMTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RMTI Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comRockwell Medical, Inc. (NASDAQ:RMTI) Expected to Post Q1 2024 Earnings of ($0.05) Per ShareMarch 27, 2024 | americanbankingnews.comRockwell Medical, Inc. (NASDAQ:RMTI) Forecasted to Post Q4 2024 Earnings of ($0.01) Per ShareMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 26, 2024 | finance.yahoo.comRockwell Medical Full Year 2023 Earnings: EPS Beats ExpectationsMarch 26, 2024 | americanbankingnews.comRockwell Medical (NASDAQ:RMTI) Price Target Cut to $9.00 by Analysts at HC WainwrightMarch 25, 2024 | businesswire.comRockwell Medical Named 'Great Place to Work' for Second Year in a RowMarch 24, 2024 | finance.yahoo.comAnalysts Have Been Trimming Their Rockwell Medical, Inc. (NASDAQ:RMTI) Price Target After Its Latest ReportMarch 23, 2024 | seekingalpha.comRockwell Medical, Inc. (RMTI) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 23, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Rockwell Med amidst Strategic Growth and Operational EfficiencyMarch 22, 2024 | americanbankingnews.comRockwell Medical (NASDAQ:RMTI) Stock Price Passes Above 200-Day Moving Average of $1.73March 22, 2024 | finance.yahoo.comQ4 2023 Rockwell Medical Inc Earnings CallMarch 21, 2024 | benzinga.comRockwell Medical: Q4 Earnings InsightsMarch 21, 2024 | marketwatch.comRockwell Medical Shares Rise After Narrower 4Q Loss, Higher SalesMarch 21, 2024 | msn.comRMTI Stock Earnings: Rockwell Medical Beats EPS, Misses Revenue for Q4 2023March 21, 2024 | sfgate.comRockwell Medical: Q4 Earnings SnapshotMarch 21, 2024 | businesswire.comRockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023March 20, 2024 | markets.businessinsider.comRockwell Medical earnings preview: what Wall Street is expectingMarch 18, 2024 | markets.businessinsider.comRockwell Medical Inc Registered Shs hosts conference call for investorsFebruary 14, 2024 | finance.yahoo.comRockwell Medical (RMTI) Flat As Market Gains: What You Should KnowFebruary 8, 2024 | finance.yahoo.comRockwell Medical to Release Fourth Quarter and Full-Year 2023 Results on Thursday, March 21, 2024January 23, 2024 | morningstar.comRockwell Medical Inc RMTIJanuary 8, 2024 | msn.comRockwell Medical provides Q4 and fiscal 2023 forecastJanuary 8, 2024 | finance.yahoo.comRockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending FundDecember 21, 2023 | benzinga.comRockwell Medical Stock (NASDAQ:RMTI) Dividends: History, Yield and DatesNovember 30, 2023 | seekingalpha.comReturning To Rockwell Medical: Buy At 65% Of RevenueNovember 17, 2023 | finance.yahoo.comRockwell Medical, Inc. (NASDAQ:RMTI): Are Analysts Optimistic?See More Headlines Receive RMTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rockwell Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:RMTI CUSIP77437410 CIK1041024 Webwww.rockwellmed.com Phone(248) 432-1362Fax248-960-9119Employees237Year Founded1995Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+324.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,440,000.00 Net Margins-10.09% Pretax Margin-10.09% Return on Equity-39.17% Return on Assets-13.87% Debt Debt-to-Equity Ratio0.46 Current Ratio1.73 Quick Ratio1.38 Sales & Book Value Annual Sales$83.61 million Price / Sales0.58 Cash Flow$0.02 per share Price / Cash Flow85.00 Book Value$0.75 per share Price / Book2.20Miscellaneous Outstanding Shares29,330,000Free Float28,690,000Market Cap$48.39 million OptionableOptionable Beta1.16 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Mark Strobeck Ph.D. (Age 53)President, CEO & Director Comp: $643.41kMs. Megan C. Timmins (Age 51)Executive VP, Chief Legal Officer & Secretary Comp: $518.09kMr. Jesse NeriSenior Vice President of FinanceMr. James A. McCarthySenior Vice President of Business & Corporate DevelopmentMr. Timothy T. CholeSenior Vice President of Sales & MarketingMs. Heather R. HunterSenior VP & Chief Corporate Affairs OfficerMr. David J. Kull (Age 56)Secretary Mr. Jason FinkelsteinInvestor Relations RepresentativeMore ExecutivesKey CompetitorsOcuphire PharmaNASDAQ:OCUPCheckpoint TherapeuticsNASDAQ:CKPTEyenoviaNASDAQ:EYENApollomicsNASDAQ:APLMGain TherapeuticsNASDAQ:GANXView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 698,160 shares on 3/11/2024Ownership: 3.773%Vanguard Group Inc.Bought 698,160 shares on 2/15/2024Ownership: 3.773%Citadel Advisors LLCSold 33,100 shares on 2/15/2024Ownership: 0.000%Armistice Capital LLCSold 965,000 shares on 2/13/2024Ownership: 6.501%WealthTrust Axiom LLCBought 10,400 shares on 2/5/2024Ownership: 0.111%View All Institutional Transactions RMTI Stock Analysis - Frequently Asked Questions Should I buy or sell Rockwell Medical stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RMTI shares. View RMTI analyst ratings or view top-rated stocks. What is Rockwell Medical's stock price target for 2024? 2 Wall Street research analysts have issued 12-month target prices for Rockwell Medical's shares. Their RMTI share price targets range from $5.00 to $9.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 329.4% from the stock's current price. View analysts price targets for RMTI or view top-rated stocks among Wall Street analysts. How have RMTI shares performed in 2024? Rockwell Medical's stock was trading at $1.89 on January 1st, 2024. Since then, RMTI stock has decreased by 13.8% and is now trading at $1.63. View the best growth stocks for 2024 here. When is Rockwell Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RMTI earnings forecast. How were Rockwell Medical's earnings last quarter? Rockwell Medical, Inc. (NASDAQ:RMTI) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.05. The business had revenue of $23.77 million for the quarter, compared to the consensus estimate of $23.67 million. Rockwell Medical had a negative net margin of 10.09% and a negative trailing twelve-month return on equity of 39.17%. During the same quarter in the previous year, the company posted ($0.40) earnings per share. When did Rockwell Medical's stock split? Rockwell Medical's stock reverse split before market open on Friday, May 13th 2022. The 1-11 reverse split was announced on Friday, May 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. What guidance has Rockwell Medical issued on next quarter's earnings? Rockwell Medical issued an update on its FY 2024 earnings guidance on Thursday, March, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $84.0 million-$88.0 million, compared to the consensus revenue estimate of $98.0 million. What is Robert L. Chioini's approval rating as Rockwell Medical's CEO? 6 employees have rated Rockwell Medical Chief Executive Officer Robert L. Chioini on Glassdoor.com. Robert L. Chioini has an approval rating of 22% among the company's employees. This puts Robert L. Chioini in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Rockwell Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rockwell Medical investors own include Immunomedics (IMMU), JinkoSolar (JKS), Seagen (SGEN), Geron (GERN), OPKO Health (OPK), Amarin (AMRN), Gilead Sciences (GILD), ImmunoGen (IMGN), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV). Who are Rockwell Medical's major shareholders? Rockwell Medical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (6.50%), Vanguard Group Inc. (3.77%), Vanguard Group Inc. (3.77%), Perkins Capital Management Inc. (1.23%), Raymond James & Associates (0.78%) and WealthTrust Axiom LLC (0.11%). View institutional ownership trends. How do I buy shares of Rockwell Medical? Shares of RMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RMTI) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rockwell Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.